peptide purity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Avutometinib/defactinib, sold under the brand name Avmapki Fakzynja Co-Pack, is a co-packaged medication used for the treatment of ovarian cancer. It contains the anti-cancer medications avutometinib, a kinase inhibitor, as the potassium salt; and defactinib, a kinase inhibitor, as the hydrochloride. It is taken by mouth. The most common adverse reactions including laboratory abnormalities, include increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count. Avutometinib/defactinib was approved for medical use in the United States in May 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
==== Conceptual history ==== In the two-part episodes "Colony" and "End Game", Chris Carter and Frank Spotnitz along with some help from David Duchovny created what would become a recurring character named the Alien Bounty Hunter. According to Carter, Duchovny came to him and said "wouldn't it be great if we had like an alien bounty hunter?" Carter was positive towards the idea and acted upon it. The actor Brian Thompson auditioned for the role in a casting session, where he was competing with another actor. Spotnitz and Carter did not have much time to cast this character, but they knew this casting would be important since they intended the character to become a recurring character. Thompson was chosen according to Spotnitz because he had a very "distinctive look" about him, most notably his face and mouth. After casting him, they told Thompson's agent that he needed a hair cut, because he was originally envisioned as a U.S. Air Force pilot who'd been shot down. When Thompson came to Vancouver, British Columbia, Canada there had been some "misunderstanding" between them, and he had not been told of the hair cut. So the hairstyle seen in this and every episode since was a "compromise" between Thompson and the producers.
== Emulsifiers == Lecithins, monoglycerides, diglycerides, and DATEM are considered emulsifiers. They disperse fat more evenly throughout the dough, helping it to trap more of the carbon dioxide bubbles produced by yeast. Lecithin added at a rate of 0.25-to-0.6% of the flour weight acts as a dough conditioner. Liquid soy lecithin may be used at a rate of up to 2% of the fat weight. It may be preferred to base the percentage on fat because lecithin dissolves well in warm fats. Based on total weight, egg yolk contains about 9% lecithin. Monoglycerides and diglycerides replace egg lecithin in baked goods. Emulsifiers have antistaling effects and tend to produce a finer grain, softer crumb, and with longer proof times, increased baked volumes.
Sources: en.wikipedia.org
=== Availability === Cyproheptadine is available widely throughout the world. This includes in Australia, Canada, Europe, Hong Kong, India, Japan, Mexico, Turkey, the United Kingdom, and the United States, among others.
== Research == Bifidobacterium animalis subspecies lactis BB-12 administered in combination with other probiotics has shown "a trend toward increased remission" in a study of 32 patients with ulcerative colitis. Research on Bifidobacterium animalis supplementation in preterm infants, as detailed in the systematic review by Szajewska et al., a meta-analysis of four randomized controlled trials (RCTs) involving a total of 324 infants, has shown promising results. These include increased fecal bifidobacteria counts, reduced Enterobacteriaceae and Clostridium spp counts, as well as improvements in stool pH, fecal calprotectin concentrations, fecal immunoglobulin A levels, and short-chain fatty acid concentrations. However, the analysis did not find significant effects on the risk of necrotizing enterocolitis stage ≥2, risk of sepsis, or use of antibiotics compared to controls.
The discovery of nuclear fission occurred in 1938 in the buildings of the Kaiser Wilhelm Society for Chemistry, today part of the Free University of Berlin, following over four decades of work on the science of radioactivity and the elaboration of new nuclear physics that described the components of atoms. In 1911, Ernest Rutherford proposed a model of the atom in which a very small, dense and positively charged nucleus of protons was surrounded by orbiting, negatively charged electrons (the Rutherford model). Niels Bohr improved upon this in 1913 by reconciling the quantum behavior of electrons (the Bohr model). In 1928, George Gamow proposed the liquid-drop model, which became essential to understanding the physics of fission. In 1896, Henri Becquerel had found, and Marie Curie named, radioactivity. In 1900, Rutherford and Frederick Soddy, investigating the radioactive gas emanating from thorium, "conveyed the tremendous and inevitable conclusion that the element thorium was slowly and spontaneously transmuting itself into argon gas!" In 1919, following up on an earlier anomaly Ernest Marsden noted in 1915, Rutherford attempted to "break up the atom." Rutherford was able to accomplish the first artificial transmutation of nitrogen into oxygen, using alpha particles directed at nitrogen 14N + α → 17O + p. Rutherford stated, "...we must conclude that the nitrogen atom is disintegrated," while the newspapers stated he had split the atom.
Sources: en.wikipedia.org
Most drugs are taken orally and are absorbed through the gastrointestinal tract. Antacids would increase the pH environment in the stomach and cause premature release of enteric coated drugs, which are designed to be protected from an acidic environment in stomach. For example, proton-pump inhibitors (PPIs) are enteric coated to protect them from decomposition under an acidic environment. Co-administration of antacids with PPIs would lead to premature release into acidic gastric environments and inactivate PPIs before absorption. These types of pharmacokinetics antagonism should be carefully avoided to prevent loss of drug efficacy. Since most drugs are either weakly acidic or weakly basic, modified pH would also affect the location at which the drug is deionised, thus affecting the required time for absorption and onset.
=== 1989 Kramatorsk, Ukraine === The 1989 Kramatorsk incident happened in 1989 when a small capsule 8 by 4 millimetres (0.3 by 0.2 inches) in size of caesium-137 was found inside the concrete wall of an apartment building in Kramatorsk, Ukrainian SSR. It is believed that the capsule, originally a part of a measurement device, was lost in the late 1970s and ended up mixed with gravel used to construct the building in 1980. Over 9 years, two families had lived in the apartment. By the time the capsule was discovered, 6 residents of the building had died, 4 from leukemia and 17 more receiving varying doses of radiation.
===== Sweden ===== Cannabidiol is classified as a medical product in Sweden. However, in July 2019, Supreme Court of Sweden ruled that CBD oil with any concentration of THC falls under the narcotic control laws.
Evidence from the study of strontium, carbon and oxygen isotopic composition of remains of Notiomastodon platensis from Pleistocene sites in the states of Pernambuco, Paraíba and Sergipe (Brazil), indicative of a predominantly C4-based diet of the studied individuals and indicating that the studied sample included both sedentary and mobile individuals, is presented by Cruz et al. (2026). The first complete skull of a member of the genus Cuvieronius (C. cf. tropicus) from North America reported to date is described from the Pleistocene (Irvingtonian) strata of the Camp Rice Formation (New Mexico, United States) by Houde et al. (2026), who argue that North/Central American and South American members of the genus Cuvieronius likely represent two distinct cryptic species. González-Guarda et al. (2026) reconstruct the environment of late Pleistocene Notiomastodon platensis and Cuvieronius hyodon from Ecuador on the basis of their tooth wear and carbon isotopic composition of their tooth enamel, interpreted as indicative of predominantly open and dry habitats. Kumar (2026) reports the first discovery of fossil material of Anancus sivalensis from Indian Siwaliks, recovered from the Pliocene Tatrot Formation in Himachal Pradesh.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.